Search Results

Saluda Medical, Inc. announced the appointment of Jim Erickson as Chief Financial Officer.

Saluda Medical, Inc. today announced the company’s data will be presented at the North American Neuromodulation Society (NANS) 2024 Annual Meeting, taking place January 18-21.

Saluda Medical, Inc. (“Saluda Medical”) today announced that the U.S. Food and Drug Administration (FDA) has approved MRI conditional labeling for the Evoke® System, the first and only precision, dose-control spinal cord stimulation (SCS) therapy powered by SmartLoop™ technology.

Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation, today announced that late-breaking data from the landmark EVOKE Clinical Trial was presented at the 2023 North American Neuromodulation Society (NANS) Annual Meeting.

Saluda Medical Pty Limited, a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced neural activation and sensing technologies, announced the appointment of Laureen DeBuono to its board of directors.

Saluda Medical, Inc. announced the publication of new health economic data in The Clinical Journal of Pain that provides the strongest ever economic case for the use of Evoke® Closed-Loop SCS with physiologic SmartLoop™ technology over open-loop SCS therapy.

Meihua International Medical Technologies Co., Ltd., a reputable manufacturer and provider of Class I, II and III disposable medical devices with operating subsidiaries in China, announced that its board of directors has approved and authorized a share repurchase program of up to $3 million of the Company’s outstanding ordinary shares.